Literature DB >> 33693570

VEXAS syndrome: still expanding the clinical phenotype.

Artem Oganesyan1, Vincent Jachiet2, Francois Chasset3, Pierre Hirsch4, Mehdi Hage-Sleiman4, Bettina Fabiani5, Paul Duriez6, Sophie Georgin-Lavialle7, Francois Delhommeau4, Yervand Hakobyan1, Olivier Fain2, Arsène Mekinian2.   

Abstract

Keywords:  UBA1; VEXAS syndrome; pneumopathy

Year:  2021        PMID： 33693570     DOI： 10.1093/rheumatology/keab225

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  3 in total

1.  USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still's Disease in Elderly Patients.

Authors:  Marion Delplanque; Achille Aouba; Pierre Hirsch; Pierre Fenaux; Julie Graveleau; Florent Malard; Damien Roos-Weil; Nabil Belfeki; Louis Drevon; Artem Oganesyan; Matthieu Groh; Matthieu Mahévas; Jerome Razanamahery; Gwenola Maigne; Matthieu Décamp; Sébastien Miranda; Thomas Quemeneur; Julien Rossignol; Laurent Sailler; Marie Sébert; Louis Terriou; Anna Sevoyan; Yervand Hakobyan; Sophie Georgin-Lavialle; Arsène Mekinian
Journal:  J Clin Med       Date:  2021-11-27       Impact factor: 4.241

2.  VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis.

Authors:  Francesco Muratore; Chiara Marvisi; Paola Castrignanò; Davide Nicoli; Enrico Farnetti; Orsola Bonanno; Rosina Longo; Piera Zaldini; Elena Galli; Nicholas Balanda; David B Beck; Peter C Grayson; Nicolò Pipitone; Luigi Boiardi; Carlo Salvarani
Journal:  Arthritis Rheumatol       Date:  2022-03-03       Impact factor: 15.483

3.  Dominance of an UBA1 mutant clone over a CALR mutant clone: from essential thrombocytemia to VEXAS.

Authors:  Mehdi Hage-Sleiman; Sophie Lalevée; Hélène Guermouche; Fabrizia Favale; Michael Chaquin; Maxime Battistella; Jean-David Bouaziz; Martine Bagot; François Delhommeau; Florence Cordoliani; Pierre Hirsch
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.